We present a case of recovery from fulminant hepatic failure secondary to high serum levels of fluconazole precipitated by amphotericin B induced renal dysfunction. Fluconazole dose adjustment or alternative antifungal treatment should be considered in patients with impaired renal function.
JacobsonM.A., HanksD.K., FerrellL.D.Fatal acute hepatic necrosis due to fluconazole. Am J Med1994; 96: 188–190.
2.
GearhartM.Worsening of liver function with fluconazole and review of azole antifungal hepatoxicity. Ann Pharmacother1994; 28: 1177–1181.
3.
BronsteinJ-A, GrosP., HernandezE., LarroqueP., MolineC.Fatal acute hepatic necrosis due to dose-dependent fluconazole hepatotoxicity. Clin Infect Dis1997; 5: 1266–1267.
4.
DebruyneD., RyckelynckJ-P. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet1993; 24: 10–27.
5.
GoaK.L., BarradellL.B.Fluconazole an update of its pharmacokinetic and pharmacodynamic properties and therapeutic use in major superficial and systemic mycoses in immunocom-prised patients. Drugs1995; 50: 658–690.
6.
BorinM.T., CoxS.R., HermanB.D., CarelB.J., AndersonR.D., FreimuthW.W.Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients. Antimicrob Agents Chemother1997; 41: 1892–1897.
7.
LeendersA.C., ReissP., PortegiesP.. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS1997; 11: 1463–1471.
8.
GrantS.M., ClissoldSPFluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs1990; 39: 877–916.
9.
HarrisS.C., WallaceJ.E., FouldsG., RinaldiM.G.Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen selective detection. Antimicrob Agents Chemother1989; 33: 714–716.
10.
GuptaA.K., SaunderD.N., ShearN.H.Antifungal agents: An overview. Part II. J Am Acad Dermatol1994; 30: 911–924.
